RALES
1999
Randomized Aldactone Evaluation Study
In 1,663 patients with severe HFrEF on ACEi, spironolactone 25 mg reduced all-cause mortality compared with placebo.
Result
Efficacy: All-cause mortalityRR 0.70 (95% CI 0.60-0.82) · P < 0.001
Below 1 favours spironolactone 25 mg, above 1 favours placebo.
- Absolute difference
- 11 points
- NNT
- 10
Absolute difference and NNT are derived from the event rates.
Also reported: (30% RRR). Gynaecomastia 10%.
- Subtopic
- MRA
- Design
- Double-blind RCT, terminated early
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Source
- Pitt B, et al. N Engl J Med. 1999;341(10):709-717.doi 10.1056/NEJM199909023411001
Discussion & critique
Pre-eplerenone era. Real-world hyperkalaemia rose sharply after publication (Juurlink BMJ 2004), underscoring the gap between trial protocol and practice monitoring.